Cancer in Singapore

IARC estimates 19,290 new cancer cases and 7,612 cancer deaths in Singapore in 2024; the commonest new cancers are colorectum, breast and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 296 trials with a site there, 3 institutions, 8 companies and 5 people, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

19,290

all cancers

Deaths

7,612

all cancers

Incidence rate

202.9

per 100,000, age-standardised

Mortality rate

70.6

per 100,000, age-standardised

Cumulative risk

20.2%

of a cancer by age 74

Population

5,832,390

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Colorectum	3,003	30.0	Colorectal cancer
Breast	2,959	67.9	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	1,951	18.4	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Prostate	1,644	32.1	Prostate cancer
Liver and intrahepatic bile ducts	936	9.0	Hepatocellular carcinoma
Corpus uteri	901	21.4	Endometrial cancer
Non-Hodgkin lymphoma	767	8.2	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Pancreas	691	6.5	Pancreatic ductal adenocarcinoma
Stomach	633	5.9	Gastric & gastro-oesophageal junction cancer
Thyroid	607	7.5	Thyroid cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	1,529	13.7	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	1,155	10.4	Colorectal cancer
Liver and intrahepatic bile ducts	693	6.3	Hepatocellular carcinoma
Breast	590	11.8	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Pancreas	570	5.2	Pancreatic ductal adenocarcinoma
Stomach	380	3.4	Gastric & gastro-oesophageal junction cancer
Prostate	298	5.3	Prostate cancer
Non-Hodgkin lymphoma	248	2.2	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Leukaemia	204	2.0	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Ovary	166	3.5	Ovarian cancer

Incidence: method 3a, national mortality estimates applied to model-based mortality-to-incidence ratios (country-specific registry data).
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Singapore”, in South-Eastern Asia (Asia), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

296 trials in OnCo · 102 recruiting overall

296 trials

Trial			Lead sponsor
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497	Phase 3	Recruiting	Merck Sharp & Dohme LLC	244	2026-10-07
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa NCT06091865	Phase 3	Recruiting	Regeneron Pharmaceuticals	194	2026-10-07
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	58	2026-10-07
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Re NCT05730036	Phase 3	Recruiting	Regeneron Pharmaceuticals	159	2026-10-07
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati NCT07195695	Phase 3	Recruiting	Boehringer Ingelheim	202	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip NCT06793215	Phase 3	Recruiting	Hoffmann-La Roche	288	2026-10-06
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) NCT06979596	Phase 2	Recruiting	Merck Sharp & Dohme LLC	60	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL NCT04924075	Phase 2	Recruiting	Merck Sharp & Dohme LLC	84	2026-10-06
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NCT06216301	Phase 3	Recruiting	NovoCure GmbH	104	2026-10-06
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer NCT07173751	Phase 3	Recruiting	BioNTech SE	212	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094	Phase 3	Recruiting	Genmab	177	2026-10-06
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult NCT06568939	Phase 2	Recruiting	AbbVie	82	2026-10-05
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07005102	Phase 2/3	Recruiting	AbbVie	65	2026-10-05
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521	Phase 3	Recruiting	Relay Therapeutics, Inc.	243	2026-10-05
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422	Phase 3	Recruiting	Merck Sharp & Dohme LLC	242	2026-10-02
FORTIFI-HN01 NCT06788990	Phase 2/3	Recruiting	Bicara Therapeutics	231	2026-10-02
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma NCT07491445	Phase 3	Recruiting	Revolution Medicines, Inc.	82	2026-10-02
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	49	2026-10-02
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750	Phase 1/2	Recruiting	PMV Pharmaceuticals, Inc	76	2026-10-02
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell NCT07361497	Phase 3	Recruiting	Bristol-Myers Squibb	260	2026-09-30
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P NCT07361510	Phase 3	Recruiting	Bristol-Myers Squibb	284	2026-09-30
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941	Phase 2	Recruiting	AstraZeneca	52	2026-09-30

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Singapore, captured 2026-10-07 to 2026-10-10. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Singapore is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

3 institutions

National Cancer Centre Singapore National University Hospital / National University Cancer Institute, Singapore Singapore Cancer Society

8 companies

Axcynsis Therapeutics Hummingbird Bioscience Intra-IMMUSG KYAN Technologies Lucence Mirxes Prestige Biopharma Tikva Allocell

5 people

People whose main affiliation in OnCo is an institution or company in Singapore.

Chee Cheng Ean Goh Boon Cher Jimmy So Lim Soon Thye Rebecca Dent

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Singapore is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

From the country research ranking

Research funders: National Medical Research Council (NMRC).
Named in the ranking: National Cancer Centre Singapore and Singapore Translational Cancer Consortium.

From the country ranking's hand-curated row; follow its source before relying on a figure.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Singapore's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Singapore, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Singapore's own sources.

Singapore is not among the 60 countries ranked in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today; Singapore fact sheet.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/sg.json; every country: /api/v1/countries.json.